Evaluation the effectiveness in treatment of multiple myeloma \r\n', u'patient with VAD (Vincristin - Adriamycin - Dexamethason) \r\n', u'

ABSTRACT

Background: Multiple myeloma is a debilitating malignancy that is part of a spectrum of diseases ranging from monoclonal gammopathy of unknown significance to plasma cell leukemia. Objective: To evaluate the effectiveness in treatment of multiple myeloma with VAD. Subjects and method: A study included 26 patients with multiple myeloma diagnosed according to Tubiana - 1993 criteria, who treated by VAD at Bach Mai Hospital, from January 1998 to December 2006. This was a retrospective combined to longitudinal follow-up examination study. Results: Response rate to treatment was 75%, complete response rate was 41.7%. Remission rate was 91.67%, complete remission rate was 66.7%. The parameters such as hemoglobin, speed of blood precipition in the first hour, globulin, and creatinine changed statistically significant after treatment. The average survival time of the patients was 30.13 \xb1 4.8 months. Survival rate of 1 year after diagnosis was 80%, at 3 years after diagnosis was 26.67% and more than 5 years after diagnosis was 6.67%. Conclusion: VAD had relatively good results in treatment of multiple myeloma.